| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 16 | 2024 | 965 | 2.610 |
Why?
|
| Neurology | 10 | 2016 | 70 | 2.040 |
Why?
|
| Ischemic Attack, Transient | 6 | 2023 | 181 | 1.990 |
Why?
|
| Receptors, AMPA | 11 | 2009 | 66 | 1.530 |
Why?
|
| Clinical Clerkship | 8 | 2016 | 116 | 1.520 |
Why?
|
| Brain Ischemia | 6 | 2023 | 398 | 1.180 |
Why?
|
| Calcium | 16 | 2007 | 1156 | 1.170 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2024 | 7 | 1.110 |
Why?
|
| Neurons | 19 | 2011 | 1547 | 1.070 |
Why?
|
| Clinical Competence | 4 | 2015 | 756 | 0.820 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2023 | 107 | 0.820 |
Why?
|
| Glutamic Acid | 8 | 2007 | 152 | 0.810 |
Why?
|
| Students, Medical | 4 | 2015 | 385 | 0.810 |
Why?
|
| Education, Medical, Undergraduate | 4 | 2016 | 160 | 0.790 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2023 | 134 | 0.770 |
Why?
|
| Foramen Ovale, Patent | 1 | 2021 | 18 | 0.770 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 73 | 0.760 |
Why?
|
| Motor Neurons | 4 | 2001 | 162 | 0.700 |
Why?
|
| Neurologic Examination | 2 | 2020 | 118 | 0.700 |
Why?
|
| Stroke, Lacunar | 2 | 2018 | 4 | 0.680 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 131 | 0.640 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 378 | 0.630 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 29 | 0.610 |
Why?
|
| Brain | 5 | 2024 | 2216 | 0.610 |
Why?
|
| Aspirin | 4 | 2023 | 156 | 0.580 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 131 | 0.570 |
Why?
|
| Kainic Acid | 8 | 2001 | 22 | 0.570 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 262 | 0.560 |
Why?
|
| Purkinje Cells | 6 | 1999 | 80 | 0.540 |
Why?
|
| Patient Simulation | 1 | 2015 | 42 | 0.530 |
Why?
|
| Statistics as Topic | 2 | 2015 | 238 | 0.530 |
Why?
|
| Heart Diseases | 1 | 2018 | 290 | 0.520 |
Why?
|
| Cells, Cultured | 21 | 2014 | 2819 | 0.520 |
Why?
|
| Hypertension | 1 | 2024 | 1142 | 0.510 |
Why?
|
| Cerebral Cortex | 3 | 2011 | 584 | 0.510 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 151 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1375 | 0.480 |
Why?
|
| Intracranial Hemorrhages | 5 | 2023 | 120 | 0.470 |
Why?
|
| Inpatients | 4 | 2023 | 298 | 0.470 |
Why?
|
| Nerve Degeneration | 4 | 2011 | 83 | 0.470 |
Why?
|
| Patch-Clamp Techniques | 9 | 2011 | 396 | 0.460 |
Why?
|
| Nitric Oxide | 4 | 2011 | 278 | 0.440 |
Why?
|
| Rats | 21 | 2007 | 3992 | 0.440 |
Why?
|
| Pyramidal Cells | 3 | 2007 | 80 | 0.440 |
Why?
|
| Echocardiography | 1 | 2018 | 911 | 0.440 |
Why?
|
| Tunicamycin | 1 | 2012 | 12 | 0.430 |
Why?
|
| Cerebellum | 7 | 2014 | 247 | 0.420 |
Why?
|
| Inclusion Bodies | 1 | 2012 | 34 | 0.420 |
Why?
|
| Ammonia | 1 | 2011 | 38 | 0.420 |
Why?
|
| Hyperammonemia | 1 | 2011 | 11 | 0.420 |
Why?
|
| Brain Edema | 1 | 2011 | 50 | 0.410 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 42 | 0.400 |
Why?
|
| Recurrence | 5 | 2022 | 1139 | 0.390 |
Why?
|
| Spinal Cord | 3 | 2001 | 249 | 0.380 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 895 | 0.380 |
Why?
|
| Educational Measurement | 1 | 2012 | 226 | 0.380 |
Why?
|
| Thrombectomy | 5 | 2024 | 158 | 0.370 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 1221 | 0.350 |
Why?
|
| Receptors, Glutamate | 3 | 2007 | 24 | 0.350 |
Why?
|
| Humans | 36 | 2024 | 86678 | 0.350 |
Why?
|
| Animals | 32 | 2014 | 26590 | 0.330 |
Why?
|
| Cell Survival | 7 | 2011 | 969 | 0.320 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 218 | 0.320 |
Why?
|
| S-Nitrosothiols | 2 | 1997 | 5 | 0.310 |
Why?
|
| Hypoxia | 2 | 2011 | 641 | 0.300 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1208 | 0.300 |
Why?
|
| Intracranial Thrombosis | 2 | 2020 | 27 | 0.300 |
Why?
|
| Hippocampus | 4 | 1999 | 442 | 0.290 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2007 | 52 | 0.290 |
Why?
|
| Organ Culture Techniques | 3 | 2012 | 135 | 0.280 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2008 | 87 | 0.270 |
Why?
|
| Fluorescent Dyes | 2 | 2004 | 242 | 0.270 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 484 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 103 | 0.260 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2000 | 10 | 0.260 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 164 | 0.250 |
Why?
|
| Pyramidal Tracts | 1 | 2004 | 16 | 0.250 |
Why?
|
| Motor Cortex | 1 | 2007 | 195 | 0.250 |
Why?
|
| Animals, Newborn | 4 | 2012 | 510 | 0.250 |
Why?
|
| Staining and Labeling | 1 | 2004 | 165 | 0.240 |
Why?
|
| Glucose | 2 | 2022 | 638 | 0.230 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 220 | 0.230 |
Why?
|
| Calcium Channels | 3 | 2001 | 182 | 0.230 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 71 | 0.230 |
Why?
|
| Retrospective Studies | 10 | 2024 | 8496 | 0.230 |
Why?
|
| Risk Factors | 6 | 2021 | 5420 | 0.230 |
Why?
|
| Blotting, Western | 4 | 2014 | 782 | 0.230 |
Why?
|
| Basilar Artery | 3 | 2023 | 41 | 0.230 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1673 | 0.220 |
Why?
|
| Cardiac Catheterization | 2 | 2021 | 291 | 0.220 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 238 | 0.220 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2001 | 182 | 0.220 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2023 | 49 | 0.220 |
Why?
|
| Mice | 11 | 2014 | 11356 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2024 | 7998 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 4 | 2012 | 3095 | 0.220 |
Why?
|
| Kinetics | 4 | 2021 | 1513 | 0.210 |
Why?
|
| Time Factors | 8 | 2020 | 5214 | 0.210 |
Why?
|
| Chicago | 4 | 2020 | 1380 | 0.200 |
Why?
|
| Cell Death | 4 | 2007 | 256 | 0.200 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 42 | 0.190 |
Why?
|
| Calcium Signaling | 1 | 2001 | 129 | 0.190 |
Why?
|
| Homeostasis | 3 | 1997 | 409 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2706 | 0.180 |
Why?
|
| Cysteine | 2 | 1997 | 135 | 0.180 |
Why?
|
| Secondary Prevention | 1 | 2020 | 162 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1824 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 97 | 0.180 |
Why?
|
| Excitatory Amino Acid Agonists | 3 | 2007 | 45 | 0.170 |
Why?
|
| Aged | 10 | 2024 | 18423 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 202 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 160 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 170 | 0.160 |
Why?
|
| Middle Aged | 11 | 2024 | 25040 | 0.160 |
Why?
|
| Neural Inhibition | 1 | 1999 | 97 | 0.160 |
Why?
|
| Male | 17 | 2024 | 40988 | 0.160 |
Why?
|
| Prognosis | 4 | 2020 | 3680 | 0.160 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 16 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 325 | 0.150 |
Why?
|
| Independent Living | 1 | 2017 | 18 | 0.150 |
Why?
|
| N-Methylaspartate | 3 | 2007 | 51 | 0.150 |
Why?
|
| Neurotoxins | 3 | 2007 | 49 | 0.150 |
Why?
|
| Female | 16 | 2024 | 44550 | 0.150 |
Why?
|
| Receptors, Kainic Acid | 2 | 1994 | 13 | 0.150 |
Why?
|
| Neurosciences | 2 | 2015 | 52 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 865 | 0.150 |
Why?
|
| Energy Metabolism | 1 | 1999 | 271 | 0.150 |
Why?
|
| Membrane Potentials | 5 | 2000 | 435 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 879 | 0.140 |
Why?
|
| Hemolysis | 1 | 1995 | 61 | 0.140 |
Why?
|
| Embryo, Mammalian | 4 | 2010 | 207 | 0.130 |
Why?
|
| Intracellular Membranes | 2 | 1995 | 117 | 0.130 |
Why?
|
| Receptors, Neurotransmitter | 2 | 1992 | 25 | 0.130 |
Why?
|
| Cytosol | 1 | 1995 | 189 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 294 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Mitochondria | 1 | 1999 | 535 | 0.130 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1135 | 0.130 |
Why?
|
| Calpain | 1 | 1995 | 111 | 0.130 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1995 | 234 | 0.120 |
Why?
|
| Paresthesia | 1 | 2014 | 16 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
| Dizziness | 1 | 2014 | 27 | 0.120 |
Why?
|
| Specialty Boards | 1 | 2014 | 24 | 0.120 |
Why?
|
| Ataxia | 1 | 2014 | 37 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2011 | 912 | 0.120 |
Why?
|
| Hypoxia, Brain | 1 | 2014 | 41 | 0.120 |
Why?
|
| Medical Records | 1 | 2014 | 119 | 0.120 |
Why?
|
| Amyloid beta-Peptides | 1 | 1995 | 203 | 0.120 |
Why?
|
| RNA, Messenger | 5 | 2010 | 1981 | 0.110 |
Why?
|
| Workload | 1 | 2014 | 128 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 1995 | 460 | 0.110 |
Why?
|
| Education, Medical | 1 | 2016 | 234 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 209 | 0.110 |
Why?
|
| Research | 1 | 2014 | 253 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2014 | 255 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2003 | 64 | 0.110 |
Why?
|
| Ibotenic Acid | 1 | 1992 | 5 | 0.110 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2012 | 8 | 0.110 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 378 | 0.100 |
Why?
|
| Cell Membrane Permeability | 2 | 2004 | 119 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 94 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2004 | 270 | 0.100 |
Why?
|
| Curriculum | 1 | 2016 | 543 | 0.100 |
Why?
|
| Electrophysiology | 3 | 2007 | 401 | 0.100 |
Why?
|
| Disease Management | 1 | 2013 | 327 | 0.100 |
Why?
|
| Nerve Net | 1 | 1995 | 366 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2001 | 78 | 0.100 |
Why?
|
| Magnesium | 1 | 1991 | 177 | 0.100 |
Why?
|
| Posterior Horn Cells | 2 | 2000 | 8 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 411 | 0.090 |
Why?
|
| Encephalitis | 1 | 2011 | 104 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2014 | 673 | 0.090 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2010 | 11 | 0.090 |
Why?
|
| Complement C5a | 1 | 2010 | 24 | 0.090 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2010 | 21 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 121 | 0.090 |
Why?
|
| Receptors, Complement | 1 | 2009 | 46 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 44 | 0.090 |
Why?
|
| Synaptic Transmission | 2 | 2004 | 222 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 636 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 425 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1753 | 0.080 |
Why?
|
| Osmolar Concentration | 3 | 1997 | 181 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 2231 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 206 | 0.080 |
Why?
|
| Acidosis, Respiratory | 1 | 2007 | 7 | 0.080 |
Why?
|
| Gene Expression | 2 | 2004 | 1284 | 0.080 |
Why?
|
| Motor Skills | 1 | 2008 | 71 | 0.080 |
Why?
|
| Hypercapnia | 1 | 2007 | 43 | 0.080 |
Why?
|
| Apoptosis | 3 | 2010 | 1683 | 0.080 |
Why?
|
| Riluzole | 1 | 2007 | 15 | 0.070 |
Why?
|
| Malonates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Sepsis | 1 | 2011 | 306 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2010 | 715 | 0.070 |
Why?
|
| Necrosis | 1 | 2007 | 204 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 747 | 0.070 |
Why?
|
| Dimerization | 2 | 2004 | 143 | 0.070 |
Why?
|
| Dipeptides | 2 | 1997 | 46 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 928 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 2264 | 0.070 |
Why?
|
| Potassium | 1 | 2007 | 281 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2007 | 347 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2007 | 193 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 407 | 0.070 |
Why?
|
| Rats, Inbred Strains | 2 | 1997 | 312 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 204 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 104 | 0.070 |
Why?
|
| Enzymes | 1 | 1985 | 47 | 0.070 |
Why?
|
| Cell Line | 2 | 2014 | 2469 | 0.060 |
Why?
|
| Axonal Transport | 1 | 2004 | 31 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 239 | 0.060 |
Why?
|
| Benzoates | 1 | 2004 | 44 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 176 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 25659 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2007 | 666 | 0.060 |
Why?
|
| Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2004 | 74 | 0.060 |
Why?
|
| Embolism | 1 | 2003 | 31 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 279 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 74 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2004 | 347 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2004 | 140 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 408 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 989 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2002 | 2 | 0.050 |
Why?
|
| Transfection | 1 | 2004 | 896 | 0.050 |
Why?
|
| Fluorometry | 3 | 1997 | 30 | 0.050 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 373 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2001 | 12 | 0.050 |
Why?
|
| Lanthanum | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2001 | 69 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 6513 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 110 | 0.050 |
Why?
|
| Benzothiadiazines | 1 | 2000 | 13 | 0.050 |
Why?
|
| Action Potentials | 1 | 2004 | 573 | 0.050 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2000 | 15 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 268 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2000 | 164 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2000 | 65 | 0.050 |
Why?
|
| Fetus | 1 | 2001 | 226 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 1578 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2010 | 36 | 0.050 |
Why?
|
| Astrocytes | 1 | 2000 | 139 | 0.050 |
Why?
|
| Hematoma | 1 | 2020 | 104 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2010 | 86 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1999 | 157 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 70 | 0.040 |
Why?
|
| Adolescent | 3 | 2023 | 8984 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1852 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 194 | 0.040 |
Why?
|
| Glycolysis | 1 | 1999 | 129 | 0.040 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Molsidomine | 1 | 1997 | 6 | 0.040 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1997 | 11 | 0.040 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1997 | 14 | 0.040 |
Why?
|
| Penicillamine | 1 | 1997 | 12 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2000 | 353 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 1242 | 0.040 |
Why?
|
| Ecuador | 1 | 2017 | 6 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1997 | 53 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| Rural Health | 1 | 2017 | 20 | 0.040 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 15 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 1999 | 314 | 0.040 |
Why?
|
| Calcium Channel Blockers | 2 | 1995 | 203 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 54 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1997 | 59 | 0.040 |
Why?
|
| Ganglia, Spinal | 3 | 1994 | 72 | 0.040 |
Why?
|
| Hemoglobins | 1 | 1997 | 179 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1055 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1749 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 196 | 0.040 |
Why?
|
| Benzamides | 1 | 1997 | 229 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 944 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 1997 | 177 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1961 | 0.040 |
Why?
|
| Models, Neurological | 1 | 1999 | 405 | 0.040 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 1995 | 4 | 0.030 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1995 | 10 | 0.030 |
Why?
|
| Pyridoxal Phosphate | 1 | 1995 | 13 | 0.030 |
Why?
|
| Suramin | 1 | 1995 | 27 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1997 | 281 | 0.030 |
Why?
|
| Nitroarginine | 1 | 1995 | 16 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1995 | 9 | 0.030 |
Why?
|
| Spectrin | 1 | 1995 | 15 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 696 | 0.030 |
Why?
|
| Calbindins | 1 | 1995 | 19 | 0.030 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1995 | 22 | 0.030 |
Why?
|
| Leucine | 1 | 1995 | 67 | 0.030 |
Why?
|
| Nucleotides | 1 | 1995 | 95 | 0.030 |
Why?
|
| Carbachol | 1 | 1995 | 34 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 181 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2010 | 3243 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 136 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 125 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 1995 | 104 | 0.030 |
Why?
|
| Capsaicin | 2 | 1993 | 44 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 639 | 0.030 |
Why?
|
| Cycloleucine | 1 | 1994 | 10 | 0.030 |
Why?
|
| RNA Cap Analogs | 1 | 2014 | 2 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Vertebral Artery | 1 | 2014 | 23 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2014 | 47 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cycloheximide | 1 | 2014 | 56 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 1995 | 190 | 0.030 |
Why?
|
| Specialization | 1 | 2014 | 65 | 0.030 |
Why?
|
| Luciferases | 1 | 2014 | 118 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1995 | 692 | 0.030 |
Why?
|
| Neuroglia | 1 | 1994 | 104 | 0.030 |
Why?
|
| Glutamates | 1 | 1994 | 89 | 0.030 |
Why?
|
| Career Choice | 1 | 2015 | 142 | 0.030 |
Why?
|
| China | 1 | 2014 | 228 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 584 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 158 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1239 | 0.030 |
Why?
|
| Plasmids | 1 | 2014 | 287 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2014 | 393 | 0.030 |
Why?
|
| Dendrites | 1 | 1993 | 99 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2000 | 1565 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1995 | 503 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1621 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 547 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 302 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 1921 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 316 | 0.030 |
Why?
|
| Biological Transport | 1 | 1992 | 396 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 388 | 0.020 |
Why?
|
| Caffeine | 1 | 1991 | 81 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2011 | 81 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 70 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 106 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 71 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 155 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 35 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1566 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 81 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 163 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1924 | 0.020 |
Why?
|
| Seizures | 1 | 1991 | 297 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 1990 | 324 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 444 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 778 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 683 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2504 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1010 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 136 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2008 | 187 | 0.020 |
Why?
|
| Memory | 1 | 2008 | 225 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 327 | 0.020 |
Why?
|
| Solvents | 1 | 1985 | 96 | 0.020 |
Why?
|
| Learning | 1 | 2008 | 281 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1985 | 287 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 1540 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2601 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1538 | 0.010 |
Why?
|
| United States | 2 | 2006 | 6681 | 0.010 |
Why?
|
| Binding Sites | 1 | 1985 | 1098 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5980 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1864 | 0.010 |
Why?
|
| Warfarin | 1 | 2002 | 103 | 0.010 |
Why?
|
| Teratocarcinoma | 1 | 2000 | 1 | 0.010 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2000 | 7 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 56 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 55 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 76 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2000 | 115 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 129 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2000 | 42 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 416 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 280 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 329 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2000 | 183 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2000 | 165 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 408 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2000 | 790 | 0.010 |
Why?
|
| Stem Cells | 1 | 2000 | 351 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 1457 | 0.010 |
Why?
|
| Muscarine | 1 | 1995 | 1 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1230 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3642 | 0.010 |
Why?
|
| Fura-2 | 1 | 1994 | 22 | 0.010 |
Why?
|
| Terpenes | 1 | 1994 | 17 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1994 | 29 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1994 | 55 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 58 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 177 | 0.010 |
Why?
|
| Nicotine | 1 | 1995 | 194 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 543 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1993 | 286 | 0.010 |
Why?
|
| Ruthenium Red | 1 | 1990 | 2 | 0.010 |
Why?
|
| Barium | 1 | 1990 | 31 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2330 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3030 | 0.010 |
Why?
|